Cancer Family
Breast Neoplasm
CI-CAN-00000007Explore in graph →
Non-malignant2,895 active trials43 approved drugs310 evidence items
- NCIt
- C2910
- OncoTree
- BNNOS
- MeSH
- D000069584
- MeSH
- D001943
Loading cancer entity…
Cancer Family
CI-CAN-00000007Explore in graph →
Clinical trials
13,871 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT02971748 | Pembrolizumab in Treating Patients With Hormone Receptor Positive, Localized Inflammatory Breast Cancer Who Are Receiving Hormone Therapy and Did Not Achieve a Pathological Complete Response to Chemotherapy | active not recruiting | Phase 2 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT06019988 | Early Point-of-Service Social and Behavioral Determinants of Health (SBDOH) Screening and Enhanced Navigation on Care Delivery for Patients With Breast Cancer(Breast_SBDOH) | active not recruiting | N/A | 2,500 | Abramson Cancer Center at Penn Medicine |
| 1 |
| Jun 11, 2026 |
| clinicaltrials |
| NCT06605261 | Effect of Yoga Program on Quality of Life in Women With Breast Cancer Receiving Endocrine Therapy | active not recruiting | N/A | 64 | Gözde GürOTHER | 1 | Jun 11, 2026 | clinicaltrials |
| NCT03202316 | Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer | active not recruiting | Phase 2 | 37 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT05558722 | Anlotinib Combined With Chemotherapy and Neoadjuvant Therapy for Hormone Receptor-positive HER-2 Negative Breast Cancer(ACNTBC) | active not recruiting | Phase 2 | 31 | Xijing HospitalOTHER | 1 | Jun 10, 2026 | clinicaltrials |
| NCT00393783 | Xenogeneic HER2/Neu DNA Immunization for Patients With Metastatic and High Risk Breast Cancer: A Phase I Study to Assess Safety and Immunogenicity | active not recruiting | Phase 1 | 13 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02263014 | Psychosocial Outcomes and Contralateral Prophylactic Mastectomy (CPM) | active not recruiting | — | 345 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02644369 | Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors(INSPIRE) | active not recruiting | Phase 2 | 100 | University Health Network, TorontoOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT02965755 | Personalized Molecular Profiling in Cancer Treatment at Johns Hopkins(IMAGE-II) | active not recruiting | N/A | 200 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 8, 2026 | clinicaltrials |
| NCT01802346 | Controlled Low Calorie Diet in Reducing Side Effects and Increasing Response to Chemotherapy in Patients With Breast or Prostate Cancer | active not recruiting | N/A | 130 | University of Southern CaliforniaOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT01953588 | Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients With Stage II-III Breast Cancer Undergoing Surgery | active not recruiting | Phase 3 | 1,473 | Alliance for Clinical Trials in OncologyOTHER | 2 | Jun 5, 2026 | clinicaltrials |
| NCT02738866 | Palbociclib With Fulvestrant for Metastatic Breast Cancer After Treatment With Palbociclib and an Aromatase Inhibitor | active not recruiting | Phase 2 | 60 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT07630558 | Investigation of the Prognostic Value of Patterns of Genomic Alterations or Protein Expression in Patients With Operated Early Breast Cancer | active not recruiting | — | 1,891 | Hellenic Cooperative Oncology GroupOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT00609791 | Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients of Different Ages With Metastatic Breast Cancer | active not recruiting | Phase 2 | 40 | City of Hope Medical CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03737695 | Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer | active not recruiting | — | 300 | Mayo ClinicOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT03768492 | Study of the Safety and Efficacy of a Caffeine-based Antifibrosis Cream in Patients With Breast Cancer Undergoing Radiation Therapy(ReDCoAT) | active not recruiting | Phase 2 | 60 | NYU Langone HealthOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT04180579 | Safety of Lower Scalp Cooling Temperature to Prevent Hair Loss From Chemotherapy in Breast Cancer Patients | active not recruiting | N/A | 34 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 4, 2026 | clinicaltrials |
| NCT00903591 | Study of Radiation Exposure and Bilateral Breast Cancer | active not recruiting | — | 1,699 | Memorial Sloan Kettering Cancer CenterOTHER | 3 | Jun 3, 2026 | clinicaltrials |
| NCT01134172 | Ethnic Differences in the Impact of Breast Cancer on Employment Status, Financial Situation, and Quality of Life | active not recruiting | — | 935 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02400190 | The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) | active not recruiting | N/A | 202 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT02927912 | Intraoperative Electron Beam Radiotherapy Boost in Treating Patients With Stage I-II Breast Cancer Undergoing Surgery With Reconstruction | active not recruiting | Phase 2 | 108 | Ohio State University Comprehensive Cancer CenterOTHER | 2 | Jun 3, 2026 | clinicaltrials |
| NCT07624734 | Impact of the Intraoperative Use of Amines in Breast Cancer Surgery on Tumor Recurrence(MASTECTAMINE) | active not recruiting | — | 250 | University Hospital, MontpellierOTHER | 1 | Jun 3, 2026 | clinicaltrials |
| NCT03429907 | An Early Stress-Reduction Intervention in Patients With Newly Diagnosed Breast Cancer | active not recruiting | N/A | 62 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT05056077 | Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)(TTBF) | active not recruiting | N/A | 353 | University of California, San FranciscoOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT07619781 | Research on the Development and Validation of Personalized Exercise Prescriptions for Breast Cancer Patients Based on Large Language Models | active not recruiting | — | 220 | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityOTHER | 1 | Jun 2, 2026 | clinicaltrials |
| NCT02810743 | Substantially Improving the Cure Rate of High-risk BRCA1-like Breast Cancer(Subito) | active not recruiting | Phase 3 | 174 | The Netherlands Cancer InstituteOTHER | 2 | Jun 1, 2026 | clinicaltrials |
| NCT05720910 | Streamlined Geriatric and Oncological Evaluation Based On IC Technology(FRONE) | active not recruiting | N/A | 720 | Institut BergoniéOTHER | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05783622 | Study of JANX008 in Subjects With Advanced or Metastatic Solid Tumor Malignancies | active not recruiting | Phase 1 | 130 | Janux TherapeuticsINDUSTRY | 1 | Jun 1, 2026 | clinicaltrials |
| NCT05203445 | A Study of Olaparib and Pembrolizumab in People With Triple Negative Breast Cancer (TNBC) or Hormone Receptor-positive HER2-negative Breast Cancer | active not recruiting | Phase 2 | 6 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT06831994 | Digital Implementation of the German S3 Clinical Practice Guideline for Multimorbidity | active not recruiting | N/A | 659 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 29, 2026 | clinicaltrials |
| NCT03524430 | RNA Disruption Assay (RDA)-Breast Cancer Response Evaluation for Individualized Therapy(BREVITY) | active not recruiting | N/A | 801 | Rna Diagnostics Inc.INDUSTRY | 7 | May 28, 2026 | clinicaltrials |
| NCT04514484 | Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV | active not recruiting | Phase 1 | 8 | National Cancer Institute (NCI)NIH | 1 | May 28, 2026 | clinicaltrials |
| NCT04568616 | Phase II Study of Neoadjuvant ArOMatase Inhibitor Therapy for ER+ Breast Cancer (NAOMI)(NAOMI) | active not recruiting | Phase 2 | 178 | Dartmouth-Hitchcock Medical CenterOTHER | 1 | May 28, 2026 | clinicaltrials |
| NCT05088785 | Dynamic and Test-retest Whole Body [18F]FES PET Imaging in Patients With Metastatic ER+ Breast Cancer(FEStastic) | active not recruiting | N/A | 15 | Amsterdam UMC, location VUmcOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT07608068 | Performance of Diffusion-weighted Imaging-based Virtual MR Elastography (vMRE) for Diagnosing Breast Cancer | active not recruiting | N/A | 238 | Yunnan Cancer HospitalOTHER | 1 | May 27, 2026 | clinicaltrials |
| NCT04588545 | Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease | active not recruiting | Phase 1 / Phase 2 | 33 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT04648904 | Study of a Shortened Radiation Therapy Schedule in People With Breast Cancer | active not recruiting | Early Phase 1 | 71 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT06772181 | A Digital Health Intervention to Improve Symptoms and Physical Activity During Breast Radiation(PRO-ACTIVE) | active not recruiting | N/A | 40 | University of WashingtonOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT00585507 | Efficacy and Safety of 500mg of Fulvestrant | active not recruiting | Phase 2 | 40 | Beth Israel Deaconess Medical CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT00877500 | Ixabepilone in Treating Participants With Significant Residual Disease of HER2/Neu Negative Invasive Breast Cancer After Systemic Therapy | active not recruiting | Phase 2 | 116 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT01251874 | Veliparib and Carboplatin in Treating Patients With HER2-Negative Metastatic Breast Cancer | active not recruiting | Phase 1 | 44 | National Cancer Institute (NCI)NIH | 1 | May 22, 2026 | clinicaltrials |
| NCT03125928 | Clinical Trial of Atezolizumab With Paclitaxel, Trastuzumab, and Pertuzumab in Patients With Metastatic HER-2 Positive Breast Cancer | active not recruiting | Phase 2 | 16 | Fox Chase Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT03449108 | LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas | active not recruiting | Phase 2 | 30 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT04522648 | Prospective Surveillance for Breast Cancer-Related Lymphedema(PROTECT) | active not recruiting | N/A | 250 | Rigshospitalet, DenmarkOTHER | 1 | May 22, 2026 | clinicaltrials |
| NCT05392608 | SEQUence of Endocrine Therapy in Advanced Luminal Breast Cancer (SEQUEL-Breast)(SEQUEL-Breast) | active not recruiting | Phase 2 | 130 | Borstkanker Onderzoek GroepNETWORK | 1 | May 22, 2026 | clinicaltrials |
| NCT06238479 | A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors(EXCEED) | active not recruiting | Phase 1 | 490 | Eli Lilly and CompanyINDUSTRY | 7 | May 22, 2026 | clinicaltrials |
| NCT03870919 | Locoregional Treatment and Palbociclib in de Novo, Treatment Naive, Stage IV ER+, HER2- Breast Cancer Patients(PALATINE) | active not recruiting | N/A | 200 | UNICANCEROTHER | 1 | May 20, 2026 | clinicaltrials |
| NCT05006196 | Contrast-Free Magnetic Resonance Imaging for Breast Disease(IMOGEN) | active not recruiting | — | 1,030 | PerspectumINDUSTRY | 1 | May 20, 2026 | clinicaltrials |
| NCT05675579 | A Phase II Study of Neoadjuvant Sacituzumab Govitecan and Pembrolizumab Therapy for Immunochemotherapy-resistant Early-stage Triple-negative Breast Cancer (TNBC) | active not recruiting | Phase 2 | 27 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2026 | clinicaltrials |
Data updated 23 days agoSource updated Jun 11, 2026source: clinicaltrials